Galderma Group AG/ADR
GDERFDrugs in Pipeline
9
Phase 3 Programs
6
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
botulinum toxin
Lateral Canthal Lines
Nemolizumab
Moderate-to-Severe Atopic Dermatitis
botulinum toxin neuromodulator
Glabellar Frown Lines (GL)
CD07805/47 gel
Rosacea
QM1114-DP
Glabellar Frown Lines
Metvix® cream
Basal Cell Carcinoma
Botulinum Toxin Type A
Glabellar Frown Lines
CD 2027
Plaque-type Psoriasis
Adapalene
Acne Scars
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
botulinum toxin | Phase 3 | Lateral Canthal Lines | - | - |
Nemolizumab | Phase 3 | Moderate-to-Severe Atopic Dermatitis | - | - |
botulinum toxin neuromodulator | Phase 3 | Glabellar Frown Lines (GL) | - | - |
CD07805/47 gel | Phase 3 | Rosacea | - | - |
QM1114-DP | Phase 3 | Glabellar Frown Lines | - | - |
Metvix® cream | Phase 3 | Basal Cell Carcinoma | - | - |
Botulinum Toxin Type A | Phase 2 | Glabellar Frown Lines | - | - |
CD 2027 | Phase 2 | Plaque-type Psoriasis | - | - |
Adapalene | Phase 2 | Acne Scars | - | - |
Frequently asked questions
What is in Galderma Group AG/ADR's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Galderma Group AG/ADR's (GDERF) pipeline across Phase 3, Phase 2. Its lead program is botulinum toxin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Galderma Group AG/ADR's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Galderma Group AG/ADR (GDERF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GDERF biotech catalysts?→
Add GDERF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Galderma Group AG/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.